Narjust Florez: Discussion with Julia Rotow about the MARIPOSA trial

Narjust Florez shared a post by IASLC on X, adding:

“At The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Considered we ARE ready for FDA approvals!

New episode today – Discussion with Julia Rotow about the MARIPOSA trial.”

Quoting IASLC’s post:

“On 8/19, the U.S. FDA approved lazertinib in combination with amivantamab for the first-line treatment of locally advanced or metastatic NSCLC, with EGFR exon 19 deletions or exon 21 L858R substitution mutations.

In this episode, Lung Cancer Considered host Narjust Florez talks to Julia Rotow from the Dana-Farber Cancer Institute about this therapy and the MARIPOSA trial, which evaluated the use of lazertinib in combination with amivantamab.

Listen here.”

Source: Narjust Florez/X and IASLC/X

Narjust Florez is the Associate Director of the Cancer Care Equity Program and a Thoracic Medical Oncologist at the Dana-Farber Brigham Cancer Center. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer. In addition, Dr. Florez founded the Florez Lab in 2019. The laboratory focuses on lung cancer, social justice issues in medicine, and medical education.

Julia Rotow is a Medical Oncologist, Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute. She completed her residency from Massachusetts General Hospital and was a Predoctoral Fellow at HHMI-NIH Research Scholars. She earned her B.A. from Harvard University.